Highlights • Patients who received no AST had a 2.5% lower 8-year DMFI rate than observed in matched patients who received ET. • Slightly more locoregional recurrences and contralateral breast cancers were observed in patients who received no AST. • These effects and side effects of ET should be discussed with patients even at a very low risk of distant metastasis. ABSTRACT Background Adjuvant systemic treatments (AST) reduce mortality, but have associated short- and long-term toxicities.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile